Continued from page 1

Bapineuzumab is given as periodic intravenous infusions, and the companies have said they are stopping development of that form but continuing to test a version that can be given as a shot.

More results on this drug and a similar one _ Eli Lilly & Co.’s solanezumab _ will be presented at a conference in Boston next month. Lilly recently announced that combined results of two large studies of solanezumab suggested some benefit on cognition.

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

.